Endothelial dysfunction in type 2 diabetes: Effect of antioxidants;Disfunção endotelial na diabetes tipo 2: Efeito de antioxidantes

Revista Portuguesa de Cardiologia

Volumn 26, Issue 6, 2007, Pages 609-619

  Sena, Cristina M ^b   Nunes, Elsa ^b   Louro, Teresa ^b   Proença, Teresa ^b   Seiça, Raquel M ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b NONE

Author keywords

Antioxidants; Atherosclerosis; Endothelial dysfunction; Oxidative stress; Type 2 diabetes

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTIOXIDANT; FREE RADICAL; MALONALDEHYDE; THIOCTIC ACID; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARBOHYDRATE METABOLISM; ENDOTHELIAL DYSFUNCTION; HYPERLIPIDEMIA; LIPID METABOLISM; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; POLYNEUROPATHY; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; RATS; THIOCTIC ACID;

EID: 34547202069     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Nam BH, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid risk profile: from the Framingham Study. Am J Cardiol. 2006; 97: 372-375.
2. National Cholesterol Education Program (NCEP) Expert Panel, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 2001; 285: 2486-2497.
3. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005; 28:1916-1921.
4. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006; 332:1115-1124.
5. Schaefer EJ, McNamara JR, Tayler T, et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol. 2004; 93: 31-39.
6. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
7. Ornish D, Brorun SE, Schermitz LW, Billings JH, Armstrong WT, Ports TA. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336: 129-33.
8. Libby P, Aikawa M, Kinlay S, Selwyn A, Ganz P. Lipid lowering improves endothelial functions. Int J Cardiol. 2000; 74:S3-S10.
9. Hamer M, Steptoe A. Influence of specific nutrients on progression of atherosclerosis, vascular function, haemostasis and inflammation in coronary heart disease patients: a systematic review. Br J Nutr. 2006; 95:849-859.
10. Sies H, Stahl W, Sevanian A. Nutritional, dietary and postprandial oxidative stress. J Nutr. 2005; 135:969-972
11. Hennig B, Toborek M, McClain CJ. High-energy diets, fatty acids and endothelial cell function: implications for atherosclerosis. J Am Coll Nutr. 2001; 20:97-105.
12. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004, 24:816-823.
13. Rimm EB, Stampfer MJ, Aschero A, Giovanuucci E, Coldits GA, Willet WC. Vitamin E consumption and risk of coronary disease in men. N Engl J Med 1993; 328:145-156.
14. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290:502-510.
15. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 2001;17:888-895.
16. Santos MS, Santos DL, Palmeira CM, Seica R, Moreno AJ, Oliveira CR. Brain and liver mitochondria isolated from diabetic Goto-Kakizaki rats show different susceptibility to induced oxidative stress. Diabetes Metab Res Rev. 2001; 17:223-230.
17. Cassini AF, Ferrali M, Pompella A, Maellaro E, Comporti M. Lipid peroxidation and cellular damage in extrahepatic tissue of bromobenzene- intoxicated mice. Am J Pathol 1986;123:520-31.
18. Jayakody L, Seneratne M, Thomson A, Kapagoda T. Endothelium-dependent relaxation in experimental atherosclerosis in the rabbit. Circ Res 1987; 50: 251-64.
19. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
20. Insull W Jr., Silvers A, Hicks L, Probstfield JL. Plasma lipid effects of three common vegetable oils in reduced-fat diets of free-living adults. Am J Clin Nutr. 1994;60:195-202.
21. Zhao G, Etherton TD, Martin KR, West SG, Gillies PJ, Kris-Etherton PM. Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr. 2004; 134:2991-2997.
22. Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnituie and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA. 2002; 99:2356-2361.
23. Hagen TM, Ingersoll RT, Lykkesfeldt J, et al. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J. 1999;13:411-418.
24. Bustamante J, Lodge JK, Marcocci L, Tritschler HJ, Packer L, Rihn BH. Alpha-lipoic acid in liver metabolism and disease. Free Radic Biol Med. 1998;24:1023-1039.
25. Lee WJ, Song KH, Koh EH, et al. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun. 2005;332:885-891.
26. Song KH, Lee WJ, Koh JM, et al. alpha-Lipoic acid prevents diabetes mellitus in diabetes-prone obese rats. Biochem Biophys Res Conunun. 2005;326:197-202.
27. Nenseter M, Gudmundesen O, Malterud K, Berg T, Drevon C. Effect of cholesterol feeding on the susceptibility of lipoproteins to oxidative modification. Biochim Biophys Acta 1994;1213: 207-14.
28. Xu Y, He Z, King GL. Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications. Curr Diab Rep. 2005;5:91-97.
29. Kocak G, Aktan F, Canbolat O, et al. Alpha-lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reactivity and morphology of vessels already damaged by streptozotocin-diabetes. Diab Nutr Metab 2000, 13:308-318.
30. Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia. 2006;49:766-774.
31. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22:1296-1301.
32. Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999;107:421-430.